# Treat the Untreated: A Primary-Care Hypertension Control Programme for Bangladesh

Diagnosis

Hypertension is a structural, regime-level health burden in Bangladesh. The curated characterization puts adult prevalence at roughly 25-30%, and the decisive detail is that it is mostly untreated. The problem is therefore not primarily one of disease incidence: it is a failure of detection, sustained treatment, and follow-up. A condition this common, left uncontrolled, drives strokes, heart attacks, and kidney failure that arrive years later as expensive, often fatal, acute events. Each untreated case is a future emergency the health system will pay for at far higher cost than the price of early control.

The economics favor action now. Blood-pressure screening is cheap, the core medicines are off-patent and inexpensive, and the clinical protocol is simple enough to be delivered by primary-care and community health workers rather than specialists. The binding gap is delivery: a standing system that finds cases, starts the right drug, keeps patients on it, and measures whether their pressure actually comes down. That system does not yet operate at scale, which is why prevalence is high but treatment is not.

Recommended actions

1. Standardize the clinical protocol (owner: DGHS). DGHS should issue a single national hypertension treatment protocol by circular, fixing a simple stepped-care drug regimen and follow-up schedule for every public facility from community clinic up to upazila health complex. Observable signal: the protocol is posted and in use at facilities, and prescribing converges on the protocol drugs.
2. Guarantee free essential antihypertensive medicines (owner: DGHS). Add the protocol's core drugs to the guaranteed free-supply list distributed through community clinics and upazila health complexes, with a dedicated procurement and stock line so patients are not turned away for stockouts. Observable signal: medicine availability at community-clinic level stays high month to month, and stockout reports fall.
3. Run opportunistic and community screening (owner: DGHS). Make blood-pressure measurement a routine step at every public outpatient visit and through community health workers, so cases are found rather than waited for. Observable signal: the number of adults screened and newly diagnosed rises, closing the gap implied by the mostly-untreated finding.
4. Build a control-rate registry, not just a coverage count (owner: DGHS). Stand up a simple patient registry that records each diagnosed patient and tracks whether their blood pressure is controlled at follow-up, reported by upazila. Observable signal: the share of registered patients who are under control becomes a published, rising number that managers are held to.
5. Anchor environmental risk reduction with the supporting body (owner: Department of Public Health Engineering, with DGHS). Coordinate with the Department of Public Health Engineering on environmental drivers of cardiovascular risk that fall in its remit, so prevention is not left entirely to the clinic. Observable signal: a joint workplan exists and reports against shared targets.

Sequencing (first 12 months)

Begin with the protocol circular and the free-medicine supply line: these are administrative actions DGHS controls directly, and they unlock everything downstream because screening is pointless if a newly found patient cannot be treated. With protocol and supply in place, switch on routine screening at outpatient and community level, which begins converting the mostly-untreated population into treated patients. Stand up the registry in parallel so that from month one the programme measures control, not just contact. By the end of the first year the chain (find, treat, supply, follow up, measure) should be operating in a first wave of upazilas, ready to scale.

Risks and constraints

The binding constraints are fiscal and managerial, not clinical. Sustained free medicine supply is a recurring budget commitment that must survive annual pressure, and stockouts are the fastest way to lose patients permanently. The harder constraint is follow-up: starting treatment is easy, keeping patients on it for life is the part systems routinely fail, so the registry and control-rate metric must be defended against being downgraded to a simple coverage tally that flatters performance. Health-worker time at the primary level is finite, so screening must be built into existing visits rather than added as a separate vertical.

Bottom line

The problem is not that Bangladesh cannot cure hypertension, it is that roughly a quarter to a third of adults have it and most are never treated. DGHS can close that gap with a standardized protocol, guaranteed free medicines, routine screening, and a registry that measures control rather than coverage, all of which are within its administrative reach.